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Background: Myeloperoxidase (MPO) expression is increased in ruptured atherosclerotic plaque and has been demonstrated to predict adverse 
clinical outcomes in the setting of acute coronary syndrome. Its relationship and relative prognostic value with other cardiac biomarkers in stable 
patients with significant atherosclerotic burden is uncertain.
Methods: We examined plasma MPO levels and incident major adverse cardiovascular events (MACE=death, myocardial infarction, stroke) over 
prospective 3-year follow-up in 2,618 patients without acute coronary syndrome (troponin negative) but significant (≥50%) stenosis in any coronary 
artery. MPO, B-type natriuretic peptide, and high-sensitivity C-reactive protein (hsCRP) were measured by Abbott Architect assays.
Results: In our cohort (age 63±11 years, 73% male, 32% with diabetes mellitus), there was only modest correlation between plasma MPO and 
hsCRP levels (Spearman’s r=0.2, p<0.001). At optimal cut-off of 322pmol/L, MPO was predictive of higher 3-year MACE (Hazard Ratio [HR] 1.71, 
95%CI 1.32-2.22, p<0.001). After adjusting for Framingham risk score, creatinine clearance, BNP (≥100pg/mL), and hsCRP (≥2mg/L), MPO 
≥322pmol/L remained independently predictive of 3-years MACE (HR 1.67; 95%CI 1.28-2.17, p<0.001).
Conclusion: Plasma MPO levels provide independent prognostic value for predicting long-term incident MACE in stable patients with significant 
atherosclerotic burden likely indicating underlying plaque vulnerability.
